SCHEMBL5230908

SCHEMBL5230908

CNC1CCN(c2cc(OC)c(-c3nc4c(C)nn(-c5ccccc5)c4c(=O)[nH]3)cc2F)CC1

nearest known ligand 0.44

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 11/20 0.44
PDE7B Q9NP56 4/20 0.44
PDE5A O76074 3/20 0.39
PDE4D Q08499 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5236084 0.87 PDE7A (0.51) PDE7APDE7BPDE4D
SCHEMBL5230898 0.84 PDE7A (0.62) PDE7APDE7BPDE4D
SCHEMBL5229855 0.82 PDE7A (0.37) PDE7APDE7BPDE5A
SCHEMBL5227959 0.81 PDE7A (0.48) PDE7APDE7BPDE5APDE4D
SCHEMBL5231475 0.81 PDE5A (0.51) PDE7APDE7BPDE5A
SCHEMBL1815883 0.81 PDE7A (0.41) PDE7APDE7BPDE5A
SCHEMBL5235214 0.81 PDE7A (0.49) PDE7APDE7BPDE5APDE4D
SCHEMBL5232794 0.79 PDE7A (0.49) PDE7APDE7BPDE5APDE4D
SCHEMBL5232284 0.79 PDE7A (0.40) PDE7APDE7B
SCHEMBL5230266 0.78 PDE7A (0.47) PDE7APDE7BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A PDE7A 4/4885PDE7B 1/4885PDE5A 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.